EUCTR2014-002169-30-GB进行中（未招募）1 期
Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy trial (PLATFORM Trial) - PLATFORM
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 770
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically verified inoperable locally advanced or metastatic adenocarcinoma of the oesophagus, oesophago-gastric junction, or stomach.
- •Completion of at least 6 cycles of first-line chemotherapy for locally advanced / metastatic disease (this must have included a platinum and fluoropyrimidine in all cases; HER-2 positive patients must have received trastuzumab alongside chemotherapy) with > stable disease on the end of treatment CT scan.
- •Disease which, following first-line chemotherapy, remains inoperable and unsuitable for definitive chemoradiotherapy.
- •Able to proceed with maintenance treatment within 28 days of the last day of the last cycle of chemotherapy.
- •Formalin fixed paraffin embedded (FFPE) blocks of diagnostic tissue available for biomarker analysis.
- •Uni-dimensionally measurable disease (CT or MRI as per RECIST).
- •Any prior chemotherapy or radiotherapy in the adjuvant setting must have been completed at least 6 months prior to the first occurrence of metastatic disease.
- •No prior radiotherapy in the advanced disease setting. Patients receiving palliative radiotherapy to sites of disease that are not measurable may be eligible and should be discussed with the Chief Investigator.
- •Male/female patients aged =18 years.
- •WHO Performance status 0, 1 or 2.
- •Patients should have a projected life expectancy of at least 3 months.
- •Adequate bone marrow function: absolute neutrophil count (ANC) =1.5x109/l; white blood cell count = 3x109/l; platelets = 100x109/l; haemoglobin (Hb) = 9g/dl (can be post-transfusion).
- •Adequate renal function: calculated creatinine clearance =50ml/minute.
- •Adequate liver function: serum bilirubin =1.5x ULN; aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase =2.5 x ULN (5 × ULN is acceptable for ALT, AST and ALP if liver metastases are present).
- •Women of childbearing potential as well as fertile men and their partners must agree to abstain from sexual intercourse or to use an effective form of contraception during the study and for 60 days following the last dose of assigned study drug(s).
- •Written informed consent must be obtained from the patient before any study-specific procedures are performed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 400
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 370
排除标准
- •Concurrent enrolment in another clinical trial unless it is an observational (non-interventional) clinical study.
- •Tumours of squamous histology.
- •Documented brain metastases, central nervous system metastases or leptomeningeal disease.
- •Patients who have not recovered from clinically significant effects of any prior surgery, radiotherapy or any other anti-neoplastic therapies. All toxicities must have resolved to grade 1 or less, with the exception of peripheral neuropathy which must be < grade 2 according to NCI CTCAE version 4.0.
- •Any major surgery within 4 weeks prior to the start of study treatment.
- •Uncontrolled hypertension (systolic blood pressure >180 mm Hg or diastolic blood pressure >100 mm Hg).
- •Clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery disease, symptomatic congestive heart failure, uncontrolled cardiac dysrhythmia, or myocardial infarction within the last 12 months. Patients with any prior history of clinically significant cardiac failure are excluded from study entry.
- •History of interstitial lung disease (e.g., pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest CT scan.
- •Lack of physical integrity of the upper gastro-intestinal tract, malabsorption syndrome, or inability to take oral medication.
- •Patients who are pregnant or lactating.
- •Known positive tests for human immunodeficiency virus (HIV) infection, hepatitis A or C virus, acute or chronic active hepatitis B infection.
- •Other clinically significant disease or co-morbidity which may adversely affect the safe delivery of treatment within this trial.
- •Any other malignancies within the last 3 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix).
- •Treatment with another investigational agent within 30 days of commencing study treatment.
研究者
相似试验
已完成
2 期
Phase II Feasibility Study of Gold Fiducial Markers forSurgical-Pathological Localisation and Chemotherapy ResponseAssessment in the Multi-Disciplinary Team Management ofOesophageal-Gastric CancerOesophageal - gastric cancerCancer - Oesophageal (gullet)Cancer - StomachACTRN12613000387729Austin Health20
招募中
不适用
Strong for Oesophago-gastric Cancer Surgery - prehabilitation program for people with stomach cancer.Oesophageal cancerCancer - Oesophageal (gullet)Cancer - StomachGastric cancerACTRN12623000183684Austin Health180
已完成
不适用
Study of treatment for esophageal cancerEsophageal cancerJPRN-UMIN000040909Graduate School of Medical Sciences,Kyushu University26
进行中（未招募）
不适用
eo-adjuvant behandling av esofagus-cardia cancer inför kurativt syftande resektion. Jämförande studie mellan kemo- och radiokemobehandling. - Neo-adjuvant behandling av esofagus-cardia cancerCancer of the esophagus or gastricardia concidered to be resectable at the preoperative evaluation. The following TN stages will be enrolled: T1-3, N1, T2-3N0 and T2-3N1.EUCTR2006-001785-16-SEKarolinska universitetssjukhuset168
进行中（未招募）
不适用
Oesophageal squamous cell cancer: chemoradiotherapy versus chemotherapy and surgery - a feasibility study - Feasibility trial of chemoradiation or surgery for oesophageal canceroesophageal cancerMedDRA version: 12Level: LLTClassification code 10030151Term: Oesophageal cancerEUCTR2009-013877-16-GBniversity Hospitals Bristol NHS Foundation Trust